Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc.

World Rank (Jan-05-2024)
16,476
Market Cap (Jan-05-2024)
0.264 Billion USD
World Rank (Jul-30-2023)
16,155
Market Cap (Jul-30-2023)
0.284 Billion USD
World Rank (Jan-07-2022)
11,890
Market Cap (Jan-07-2022)
0.635 Billion USD
World Rank (Jan-01-2021)
3,915
Market Cap (Jan-01-2021)
3.452 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
AVIR
Market Cap (Mar-08-2026)
0.46
Employee Count
19
Employee Count as of Date
As on September 2020
Headquarters City/State
Massachusetts
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
351 Million USD
Annual Net Income in USD
121 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Total Assets in USD
772 Million USD
Total Liabilities in USD
62 Million USD
Total Equity in USD
710 Million USD
Balance Sheet for Period Ending
Dec-2021 ending year
Business Sector
Biopharmaceutical
Healthcare
Biotechnology
Company Website
ATEA PHARMACEUTICALS, INC.
Yahoo
Yahoo @ Nasdaq
Company Profile
Atea is a Clinical Stage Biopharmaceutical company. It is focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life threatening viral diseases. The company annual revenue is 13.6 million USD and 6,904 employees as on 2019. The headquarters is in USA.
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Medicinal Chemicals and Botanical Products

Share